Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
0000-00-00 | knjnlnlnln | nl | nl | Licensing agreement |
0000-00-00 | Compound: | sadasd | dsadasdasd | Plant acquisition |
0000-00-00 | hj | j | vhv | Validation of a production plant |
0000-00-00 | Compound: | asdasdasda | asdasdasdas | Plant acquisition |
0000-00-00 | test | test | test | Grant |
0000-00-00 | Establishment of a new subsidiary in the EU | |||
2017-02-09 | deflazacort | Marathon Pharmaceuticals (USA - IL) | Duchenne muscular dystrophy (DMD) | Granting of a Market Authorisation in the US |
2017-07-25 | baricitinib (LY3009104) | Eli Lilly (USA -IN) Incyte Corporation (USA - DE) | rheumatoid arthritis | Submission of an NDA |
2016-12-16 | CD19 specific CAR T cells also expressing an EGFRt | Juno Therapeutics (USA - WA) |
|
Granting of the Breakthrough Therapy status |
2017-04-17 | hydroxyprogesterone caproate injection | Amag Pharmaceuticals (USA - MA) | reduction of the risk of preterm birth in women who are pregnant with one baby and who have spontaneously delivered one preterm baby in the past | Submission of an sNDA |
2017-07-25 | CRISPR/Cas9 single-guide gene editing system | Crispr Therapeutics (Switzerland - UK) | Patent infringement lawsuit | |
2018-09-05 | tisagenlecleucel-T | Novartis (Switzerland) |
|
Granting of a Market Authorisation in the EU |
2017-04-25 | naltrexone HCl and bupropion HCl | Valeant Pharmaceuticals (Canada) Orexigen Therapeutics (USA - CA) | chronic weight management in adults | Acceptation for review of a NDA |
2017-04-24 | anti-thymocyte globulin (rabbit) | Sanofi (France) | prevention of acute rejection in patients receiving a kidney transplant | Granting of a Market Authorisation in the US |
2017-04-28 | BioInvent (Sweden) | Granting of a patent | ||
2017-01-19 | TG-1101 (ublituximab) and TGR-1202 | TG Therapeutics (USA - NY) | diffuse large B-cell lymphoma | Granting of the orphan status in the US |
2017-03-22 | BAX 930/SHP655 | Shire (UK - USA) | hereditary thrombotic thrombocytopenic purpura | Granting of a Fast Track status |
2016-02-03 | emricasan | Conatus Pharmaceuticals (USA - CA) | liver cirrhosis caused by NASH (non-alcoholic steatohepatitis) | Granting of a Fast Track status |
2017-05-16 | recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA | Sangamo Therapeutics (USA - CA) previously known as Sangamo Biosciences | hemophilia A | Granting of the orphan status in the EU |
2018-01-19 | adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene | Sangamo Therapeutics (USA - CA) previously known as Sangamo Biosciences | mucopolysaccharidosis type I (MPS I) | Granting of the orphan status in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+